Investment Analysts’ Recent Ratings Changes for AmerisourceBergen (ABC)

A number of research firms have changed their ratings and price targets for AmerisourceBergen (NYSE: ABC):

  • 2/8/2018 – AmerisourceBergen was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $103.00 price target on the stock. According to Zacks, “AmerisourceBergen ended the first quarter of fiscal 2018 on a solid note, beating the Zacks Consensus Estimate for both the counts. A strong guidance instills investor’s optimism on the stock. Solid performance in the Pharmaceutical Distribution Segment and World Courier business holds promise. Notably, World Courier recently obtained global Good Distribution Practices (GDP) designation. The recent takeover of H.D. Smith, the largest independent wholesaler in the United States, is also a positive. On the flip side, sluggishness in the ABCS segment is a concern. AmerisourceBergen faces headwinds, thanks to the slowdown in hepatitis C revenues and conversion of branded drugs to the lower price generics. Further, a temporary slowdown in PharMEDium's growth is expected to mar the company’s bottom line. In this regard, the company faced lower-than-expected production at PharMEDium's Memphis facility. “
  • 2/8/2018 – AmerisourceBergen had its price target lowered by analysts at Needham & Company LLC from $117.00 to $113.00. They now have a “buy” rating on the stock.
  • 2/7/2018 – AmerisourceBergen was given a new $95.00 price target on by analysts at Jefferies Group LLC. They now have a “hold” rating on the stock.
  • 2/7/2018 – AmerisourceBergen had its “outperform” rating reaffirmed by analysts at Credit Suisse Group AG. They now have a $112.00 price target on the stock, up previously from $105.00. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 2/7/2018 – AmerisourceBergen had its “hold” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $102.00 price target on the stock.
  • 2/6/2018 – AmerisourceBergen was upgraded by analysts at TheStreet from a “c” rating to a “b” rating.
  • 1/31/2018 – AmerisourceBergen was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Despite trading below the broader industry over the last year, AmerisourceBergen is expected to benefit from generics growth. The company has been actively pursuing acquisitions to strengthen its core areas. The recent takeover of H.D. Smith, the largest independent wholesaler in the United States, is worth a mention in this regard. The deal is worth for $815 million. Solid performance in the Pharmaceutical Distribution Segment is also a positive. On the flip side, AmerisourceBergen faces headwinds due to the slowdown in hepatitis C revenues and conversion of branded drugs to the lower price generics. Furthermore, a temporary slowdown in PharMEDium's growth is expected to mar the company’s bottom line. Cutthroat competition in niche space also adds to the woes.”
  • 1/24/2018 – AmerisourceBergen was given a new $100.00 price target on by analysts at Mizuho. They now have a “hold” rating on the stock.
  • 1/23/2018 – AmerisourceBergen had its price target raised by analysts at Needham & Company LLC from $88.00 to $108.00. They now have a “buy” rating on the stock.
  • 1/18/2018 – AmerisourceBergen was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $111.00 price target on the stock. According to Zacks, “Despite trading below the broader industry over the last year, AmerisourceBergen is expected to benefit from generics growth. The company has been actively pursuing acquisitions to strengthen its core areas. The recent takeover of H.D. Smith, the largest independent wholesaler in the United States, is worth a mention in this regard. The deal is worth for $815 million. Solid performance in the Pharmaceutical Distribution Segment is also a positive. On the flip side, AmerisourceBergen faces headwinds due to the slowdown in hepatitis C revenues and conversion of branded drugs to the lower price generics. Furthermore, a temporary slowdown in PharMEDium's growth is expected to mar the company’s bottom line. Cutthroat competition in niche space also adds to the woes. “
  • 1/15/2018 – AmerisourceBergen was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “AmerisourceBergen has been trading below the broader industry over the last year. However, the company is expected to benefit from generics growth. AmerisourceBergen has been actively pursuing acquisitions to strengthen its core areas. Acquisition of H.D. Smith, the largest independent wholesaler in the United States, is worthy of mention. Solid performance in the Pharmaceutical Distribution Segment is a positive. Strong sales in the oncology unit have enhanced AmerisourceBergen Drug Corporation (ABDC) sales. On the flip side, AmerisourceBergen faces headwinds due to the slowdown in hepatitis C revenues and conversion of branded drugs to the lower price generics. Furthermore, a temporary slowdown in PharMEDium's growth is expected to mar the company’s bottom line. Cutthroat competition in niche space also adds to the woes.”
  • 1/5/2018 – AmerisourceBergen was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “AmerisourceBergen has been trading below the broader industry over the last year. However, the company is expected to benefit from generics growth. AmerisourceBergen has been actively pursuing acquisitions to strengthen its core areas. Solid performance in the Pharmaceutical Distribution Segment is a positive. Strong sales in the oncology unit have enhanced AmerisourceBergen Drug Corporation (ABDC) sales.  The company has announced that it will acqure H.D. Smith, the largest independent wholesaler in the United States. On the flipside, AmerisourceBergen faces headwinds due to the slowdown in hepatitis C revenues and conversion of branded drugs to the lower price generics. Furthermore, a temporary slowdown in PharMEDium's growth is expected to mar the company’s bottom line. “
  • 1/4/2018 – AmerisourceBergen is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $105.00 price target on the stock.
  • 1/3/2018 – AmerisourceBergen was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $105.00 price target on the stock. According to Zacks, “AmerisourceBergen has been trading below the broader industry over the last year. However, the company is expected to benefit from generics growth. AmerisourceBergen has been actively pursuing acquisitions to strengthen its core areas. Solid performance in the Pharmaceutical Distribution Segment is a positive. Strong sales in the oncology unit have enhanced AmerisourceBergen Drug Corporation (ABDC) sales.  The company has announced that it will acqure H.D. Smith, the largest independent wholesaler in the United States. On the flipside, AmerisourceBergen faces headwinds due to the slowdown in hepatitis C revenues and conversion of branded drugs to the lower price generics. Furthermore, a temporary slowdown in PharMEDium's growth is expected to mar the company’s bottom line. “
  • 1/2/2018 – AmerisourceBergen was given a new $105.00 price target on by analysts at Leerink Swann. They now have a “buy” rating on the stock.
  • 12/15/2017 – AmerisourceBergen was upgraded by analysts at Goldman Sachs Group Inc from a “neutral” rating to a “buy” rating.

AmerisourceBergen Corp. (ABC) opened at $89.19 on Monday. The firm has a market capitalization of $19,592.28, a P/E ratio of 19.22, a PEG ratio of 1.43 and a beta of 1.02. AmerisourceBergen Corp. has a twelve month low of $71.90 and a twelve month high of $106.27. The company has a current ratio of 0.95, a quick ratio of 0.50 and a debt-to-equity ratio of 1.61.

AmerisourceBergen (NYSE:ABC) last issued its earnings results on Tuesday, February 6th. The company reported $1.55 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.35 by $0.20. The business had revenue of $40.47 billion for the quarter, compared to analysts’ expectations of $40.42 billion. AmerisourceBergen had a return on equity of 53.65% and a net margin of 0.66%. The business’s revenue for the quarter was up 6.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.36 EPS. research analysts predict that AmerisourceBergen Corp. will post 6.58 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, March 5th. Stockholders of record on Tuesday, February 20th will be issued a dividend of $0.38 per share. This represents a $1.52 annualized dividend and a dividend yield of 1.70%. The ex-dividend date of this dividend is Friday, February 16th. AmerisourceBergen’s dividend payout ratio is currently 32.76%.

In related news, Director Richard W. Gochnauer sold 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 29th. The stock was sold at an average price of $85.00, for a total value of $170,000.00. Following the transaction, the director now directly owns 12,947 shares in the company, valued at $1,100,495. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Dale Danilewitz sold 4,459 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The shares were sold at an average price of $78.30, for a total value of $349,139.70. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 203,077 shares of company stock worth $18,288,730. Insiders own 27.30% of the company’s stock.

AmerisourceBergen Corporation is a pharmaceutical sourcing and distribution services company. The Company’s segments include Pharmaceutical Distribution and Other. The Company provides services to healthcare providers, and pharmaceutical and biotech manufacturers. As of June 30, 2016, the Pharmaceutical Distribution segment consists of two operating segments, including the operations of AmerisourceBergen Drug Corporation (ABDC) and AmerisourceBergen Specialty Group (ABSG), which distributes specialty drugs to their customers.

Receive News & Ratings for AmerisourceBergen Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmerisourceBergen Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply